The intertwined fate of heart, kidneys, and metabolism: Mastering risk mitigation in high-risk patients
IMPORTANCE
In order to apply for CME credits, Omnihealth Practice will collect your professional details and participation results for the corresponding College/ CME Programmes Administrator.
PLEASE ENSURE YOUR ACCOUNT DETAILS ARE CORRECT, including full name, and registration number. Omnihealth Practice is not responsible for any failure on application due to error details provided by participant. Should you have any questions, please contact [email protected]
To receive a certificate, you must achieve a passing score as designated by the corresponding college/ CME Programmes Administrator. You may view or print the certificate from RECORD, but you cannot alter it.
All the CME accredited programmes on Omnihealth Practice Education Portal are approved for healthcare professionals in Hong Kong SAR ONLY.
CME released:
5 January 2026
Valid for credit through:
4 January 2027
CME accredited by:
5 January 2026 - 4 March 2026
The Hong Kong College of Pathologists - 1.0
Hong Kong College of Physicians - 1.0
CME accredited by:
5 January 2026 - 4 January 2027
Hong Kong Doctors Union - 1.0
CKMSynced Forum is a professional, integrated educational platform for Hong Kong healthcare professionals to receive the latest updates on international guidelines for cardio-renal-metabolic disease and related information, such as case reports, insightful articles and lectures. The platform includes interviews with numerous key opinion leaders (KOLs) in the field, from whom local healthcare professionals can gain valuable insights.
About the programme
In a recent lecture, Dr. Cheng Yuk Yan, Alice, emphasizes the importance of early and comprehensive screening for cardio-kidney-metabolic (CKM) syndrome. Dr. Cheng advocated for initiating empagliflozin early and noted that any specialist who recognizes the need should consider initiating it. This approach is supported by trials like the EMPA-REG OUTCOME, EMPA-KIDNEY, and the EMPEROR trials. These studies helped establish empagliflozin as a foundational "organ-protecting" therapy, which is now recommended in major international guidelines.
Disclaimer
This is an independent editorial article, published and distributed through unrestricted educational support from the pharmaceutical community, for the purpose of continuing medical education only. The views expressed in this publication reflect the experience and/or opinion of the author(s) and are not necessarily those of editors, publisher, and sponsor(s). Because of rapid advances in medicine, independent verification of clinical diagnoses, medical suitability and dosage should be made before treatment prescription. The appearance of advertisement, if any, has no influence on editorial content or presentation and does not imply the endorsement of products by the publication, or its authors and editors.